COSMIC 313: Efficacy Data
Dr Rana McKay reviews key efficacy data from the COSMIC 313 trial and discusses factors that are considered when choosing between IO-TKI or IO-IO combinations.
EP: 1.Case Presentation: A 73-Year-Old Man with Advanced Renal Cell Carcinoma (RCC)
EP: 2.Efficacy and Quality of Life Data from 5-Year Follow-Up of CheckMate 214
EP: 3.COSMIC 313: Efficacy Data
EP: 4.Cabozantinib, Nivolumab, and Ipilimumab: Rationale for Use
EP: 5.Advice for Community Oncologists Treating Patients with Advanced RCC
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC
November 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.
Read More
Understanding Clonal Hematopoiesis in Kidney Cancer Could Improve Cardiovascular Outcomes
November 11th 2023In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.
Read More
